[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100456541":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":33,"responsibleParty":61,"collaborators":20,"id":64,"slug":20,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":20,"enrollmentInfo":73,"targetDuration":20,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":86,"overallStatus":36,"whyStopped":20,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Ultra-hypofractionated radiotherapy","EXPERIMENTAL","Patients receive ultra-hypo-fractionated radiotherapy with 25Gy to 50Gy in five fractions, followed by surgery done at 1 to 2 months post-RT",[13],"Radiation: ultra-hypofractionated radiotherapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","ultra-hypofractionated radiotherapy","stereotactic ablative radiotherapy with 25 to 50Gy in five fractions given preoperatively",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Ning-Ning Lu","PRINCIPAL_INVESTIGATOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","+868611804268","Ning-Ning.Lu@hotmail.com",{"name":31,"role":27,"phone":20,"phoneExt":20,"email":32},"Shu-Lian Wang","wsl20040118@yahoo.com",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Radiotherapy Department of Cancer Hospital, Chinese Academy of Medical Sciences","RECRUITING","Beijing","Beijing Municipality","100021","China","CN",{"type":43,"coordinates":44},"Point",[45,46],116.39723,39.9075,{"lat":46,"lon":45},[49,52,55,57,59],{"name":50,"role":27,"phone":51,"phoneExt":20,"email":29},"Ningning Lu, Doctor","+86 01087787630",{"name":53,"role":27,"phone":54,"phoneExt":20,"email":32},"Shu-Lian Wang, M.D.","+86 01087788280",{"name":56,"role":24,"phone":20,"phoneExt":20,"email":20},"Nian-Zeng Xing, M.D",{"name":58,"role":24,"phone":20,"phoneExt":20,"email":20},"Shu-Lian Wang, M.D",{"name":60,"role":24,"phone":20,"phoneExt":20,"email":20},"Ning-Ning Lu, M.D.",{"type":24,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"NINGNING LU","Principle Investigator","100456541",false,"NCT05224934","Preoperative Ultra-hypofractionated Radiotherapy Followed by Surgery for Retroperitoneal Sarcoma (FUSION-01)","Full-target Ultra-hypofractionated Stereotactic Irradiation Orchestrated With Nodule Boost for Retroperitoneal Sarcoma","FUSION-01","Inclusion Criteria:\n\n* Primary soft tissue sarcoma of retroperitoneal or infra-peritoneal spaces of pelvis\n* Sarcoma not originated from bone structure, abdominal or gynecological viscera\n* All disease can be included safely within one radiotherapy field\n* Absence of extension through the sciatic notch or across the diaphragm\n* Histologically proven, excluding the following subtypes: Gastro-intestinal stromal tumors (GIST), rhabdomyosarcoma, PNET or other small round blue cells sarcoma, osteosarcoma or chondrosarcoma, aggressive fibromatosis, sarcomatoid or metastatic carcinoma\n* ECOG performance status 0 to 2\n* American Society of Anesthesiologist (ASA) score ≤2\n* Normal renal function: Calculated Creatinine Clearance ≥50ml\u002Fmin（by Cockcroft-Gault formula）and functional contralateral kidney by differential renal isotope scan\n* Normal bone marrow and hepatic function.\n* Contraception was needed for female patients of child-bearing age, or male patients whose partner had child-bearing age\n* expected life expectancy longer than 5 years\n* Written consent form was given prior to treatment\n* Can safely be treated by radiotherapy and surgery\n\nExclusion Criteria:\n\n* metastatic disease\n* Tumor was previously treated by radiotherapy\n* Involvement of liver, pancreatic head or duodenum","ALL","18 Years",{"count":74,"type":75},50,"ESTIMATED","INTERVENTIONAL",[78],"NA","To investigate the feasibility and peri-operative complications of preoperative hypo-fractionated radiotherapy followed by surgery for retroperitoneal sarcoma",[81,82,83,84,85],"Soft Tissue Sarcoma","Retroperitoneal Sarcoma","Radiotherapy Side Effect","Ultra-hypofractionated Radiotherapy","Stereotactic Ablative Radiotherapy",[87,88,89,90,91],"stereotactic ablative radiotherapy","hypofractionated radiotherapy","retroperitoneal sarcoma","soft tissue sarcoma","peri-operative complications","2025-12-04",{"date":94,"type":95},"2025-12-11","ACTUAL",{"date":97,"type":95},"2022-01-01",{"date":99,"type":75},"2027-12-31",{"name":5,"class":6},1]